Abigail Brooks, MA

Chari Cohen, DrPH, MPH, discusses the current landscape of hepatitis B management and areas she sees room for development.

Findings from a retrospective cohort study highlighted the impact of bariatric surgery on postoperative ocular disease incidence, reducing the risk of future ocular morbidity.

Household primary language was associated with vision screening, with children from non-English households exhibiting lower rates of pediatric vision screening.

Advanced kidney disease, type 2 diabetes, and high risk of disease progression were prevalent among the cohort based on records collected from the HealthVerity database.

Results highlighted an association between socioeconomic deprivation and greater risk of progression to kidney failure in patients with IgAN.

Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.

Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.

Results showed decreased mortality rates among patients with severe alcohol-associated hepatitis treated with corticosteroids after the COVID-19 pandemic.

Sumera Ilyas, MBBS, discussed cholangiocarcinoma in primary sclerosing cholangitis and the need for global efforts to improve access to more advanced diagnostic testing.

We sat down with Jessica Ferrell, PhD, to discuss key takeaways from her session about the developing role of bile acids both for and beyond cholestatic and metabolic diseases.

Results from this prospective study in Japan found older age, history of hepatocellular carcinoma, and decreased albumin level at SVR were significantly associated with liver-related mortality after SVR.

We sat down with Ana Lleo, MD, PhD, to discuss primary sclerosing cholangitis biomarkers and the need for future research in this field.

Results presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases highlighted an association between food insecurity and low household income with the risk of NAFLD in adolescents.

Phase 3 data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases demonstrated the safety and efficacy of seladelpar in patients with primary biliary cholangitis through 12 months of treatment.

Tatyana Kushner, MD, MSCE, sat down with HCPLive to discuss the White House hepatitis C elimination plan.

We sat down with Mark Sundrud, PhD, to discuss bile acids and T cells in cholestatic liver disease and the future of research regarding the interplay between intestinal and liver functions.

Data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases (AASLD) showed similar assisted reproductive technology outcomes for patients with and without chronic liver disease.

60.2% of infant living-related liver transplant recipients developed AKI within 7 days of surgery and experienced more frequent serious complications, longer hospital stays, and a greater duration of postoperative mechanical ventilation compared to those who did not develop AKI.

The FDA announced it has approved Adzynma as prophylactic or on-demand enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura.

Decreased blood serum cholesterol levels were associated with an increased risk of plasma cell neoplasm, although there was no causal association with multiple myeloma.

Preliminary data from the SPARTAN study were presented at ASN Kidney Week 2023, demonstrating sparsentan’s impact on proteinuria and total body water over time.

Disparities in nephrology were at the forefront of multiple sessions, presentations, and conversations at ASN Kidney Week 2023.

Results called attention to a greater risk of hospitalization among patients with CKD who exhibited depressive symptoms, regardless of treatment with dialysis.

Data presented at ASN Kidney Week 2023 highlighted the patient-reported difficulty of implementing physician-recommended lifestyle changes but noted significant impacts on physical health, mental health, and overall quality of life when done successfully.

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Results presented at ASN Kidney Week 2023 highlighted the importance of eGFR and albuminuria measurements for identifying risk of major adverse kidney disease events.

The study, presented at ASN Kidney Week 2023, sought to assess the impact of sociodemographic stress on outcomes in home dialysis among patients with ESRD.

Food insecurity was associated with more missed appointments and fluid or electrolyte-related hospitalizations among patients on hemodialysis, especially those under 55 years of age.

Findings presented at ASN Kidney Week 2023 highlighted an association between distance to the transplant center and increased clinic cancellations.

Data presented at ASN Kidney Week 2023 suggested male kidney donors recover greater kidney function than females after donation.